ROCKET PHARMACEUTICALS ($RCKT) posted quarterly earnings results for Q2 2026 on Monday, August 10th. The company reported earnings of -$0.15 per share, missing estimates of $0.25 by $0.40. The company also reported revenue of $0, missing estimates of $20,400,000 by $-20,400,000.
You can see Quiver Quantitative's $RCKT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ROCKET PHARMACEUTICALS Insider Trading Activity
ROCKET PHARMACEUTICALS insiders have traded $RCKT stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $RCKT stock by insiders over the last 6 months:
- GAURAV SHAH (CEO) has made 0 purchases and 5 sales selling 79,090 shares for an estimated $249,601.
- MARTIN WILSON (General Counsel) has made 0 purchases and 4 sales selling 17,652 shares for an estimated $59,290.
- JOHN MILITELLO (See Remarks) has made 0 purchases and 3 sales selling 4,965 shares for an estimated $16,581.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ROCKET PHARMACEUTICALS Hedge Fund Activity
We have seen 100 institutional investors add shares of ROCKET PHARMACEUTICALS stock to their portfolio, and 99 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP added 3,012,368 shares (+11433.4%) to their portfolio in Q1 2026, for an estimated $10,513,164
- SUVRETTA CAPITAL MANAGEMENT, LLC removed 2,992,735 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $10,444,645
- NUVEEN, LLC added 2,970,741 shares (+1880.1%) to their portfolio in Q1 2026, for an estimated $10,367,886
- STATE STREET CORP removed 2,665,868 shares (-59.4%) from their portfolio in Q2 2026, for an estimated $9,117,268
- AQR CAPITAL MANAGEMENT LLC added 2,366,402 shares (+336.4%) to their portfolio in Q1 2026, for an estimated $8,258,742
- BLACKROCK, INC. added 2,089,167 shares (+26.7%) to their portfolio in Q2 2026, for an estimated $7,144,951
- MORGAN STANLEY removed 1,921,269 shares (-48.7%) from their portfolio in Q1 2026, for an estimated $6,705,228
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ROCKET PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $RCKT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 03/27/2026
To track analyst ratings and price targets for ROCKET PHARMACEUTICALS, check out Quiver Quantitative's $RCKT forecast page.
ROCKET PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $RCKT recently. We have seen 4 analysts offer price targets for $RCKT in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $11.0 on 05/11/2026
- Jason Zemansky from B of A Securities set a target price of $9.0 on 03/30/2026
- Richard Law from Goldman Sachs set a target price of $3.0 on 03/02/2026
- Josh Schimmer from Cantor Fitzgerald set a target price of $10.0 on 02/27/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
